News Feed

Showing posts with label pharmaceuticals.. Show all posts
Showing posts with label pharmaceuticals.. Show all posts

Monday, October 13, 2014

Announcing the Accelerate Multiple Sclerosis Drug



Multiple Sclerosis (MS) is a disabling and degenerative disease of the nervous system which affects 2.3 million people worldwide and unfortunately continues to grow every year.

Madrid, M, Spain – October 14, 2014 – ANKAR PHARMA’s drug candidate aimed to fight multiple sclerosis is AP-1, a first-in-class small molecule with a dual innovative mechanism of action and high activity in preclinical models. AP-1 has shown high activity in all key components associated to MS in the worldwide accepted model of MS: the experimental allergic encephalitis (EAE) one.

AP-1 is able to decrease the clinical symptoms (neurological score) in the EAE model after chronic preventive treatment or, in the worst situation, when the compound is administered at the peak of the disease. The efficacy in this murine model is similar or better that the produced by fingolimod, the most recent approved drug for MS orally treatment. Moreover, AP-1 is able to reduce inflammation, protects olygodendrocyte from death and promotes their growth and it is able to increase remyelinization. AP-1 penetrates in the brain and can be orally administered.

Multiple Sclerosis (MS) is a disabling and degenerative disease of the nervous system which affects 2.3 million people worldwide and unfortunately continues to grow every year. The countries with the highest rate of patients affected by multiple sclerosis are the USA, Canada, the UK, Scandinavia and Australia.
Multiple Sclerosis causes progressive fatigue, muscle spasms and paralysis, incontinence, visual disturbances and other cognitive and neurological impairments. In the most severe cases, patients are unable to walk, speak, write or eventually breathe.

About ANKAR PHARMA

ANKAR PHARMA is a spin-off company born in the CSIC (Spanish Council for Research) that will help to accelerate the translation of basic research on drug discovery to clinical trials for severe human unmet diseases such as neurodegenerative disorders and metabolic diseases.  

To minimize the risk and optimize the success, ANKAR PHARMA will work by different projects supported by different partners and collaborators. All of them will be focused on new drug candidates with innovative mechanism of action for diverse diseases where no effective treatment exists. The first efforts of the company are aimed to Multiple Sclerosis (MS).

To learn more ANKAR PHARMA or AP-1 or to help support efforts, please visit:


Contact
Michael De José Belzunce
Madrid, M, Spain

Labels